NYXH Nyxoah

Publication relating to transparency notification

Publication relating to transparency notification

REGULATED INFORMATION

Publication relating to transparency notification

Mont-Saint-Guibert (Belgium), January 12, 2026, 7:00 am CET / 1:00 am ET In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

BNP Paribas Asset Management

On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of the total number of voting rights on December 31, 2025 (43,026,460).

The notification dated January 7, 2026 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a parent undertaking or a controlling person
  • Person subject to the notification requirement: BNP Paribas Asset Management SA (with address at SA 47000-75318 Paris cedex 09-France)
  • Date on which the threshold was crossed: December 31, 2025
  • Threshold that is crossed: 3%
  • Denominator: 43,026,460
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
BNP Paribas Asset Management Holding00 0.00% 
BNP Paribas Asset Management Europe SAS696,5621,409,791 3.28% 
Subtotal696,5621,409,791 3.28% 
 TOTAL1,409,79103.28%0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: The subsidiary BNP Paribas Asset Management Europe SAS is controlled by the parent company BNP Paribas Asset Management Holding. This parent company is itself controlled by the parent company BNP Paribas SA, which benefits from an exemption from aggregating its shareholdings with those of its subsidiaries investment companies, in accordance with article 21, paragraph 2 of the Royal Decree of February 14, 2008 on the disclosure of major shareholdings.
    • Additional information: The subsidiary BNP Paribas Asset Management Europe SAS is an investment company that exercises voting rights on a discretionary basis in the absence of specific instructions. Following the merger between BNP Paribas Asset Management Europe SAS and AXA Investment Managers SA on December 31, 2025, the combined positions of the two entities resulted in the crossing of the 3% threshold.

*

* *

Contact:

Nyxoah

John Landry, CFO



Attachment



EN
12/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026. Share capital: EUR 6,511,048.19 Total number of securities carrying voting rights: 43,662,403 (all ordinary shares) Total number of voting righ...

 PRESS RELEASE

Informations sur le nombre total de droits de vote et d'actions

Informations sur le nombre total de droits de vote et d'actions INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 25 février 2026, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci-dessous suite à l'émission de nouvelles actions le 20 février 2026. Capital : EUR 6.511.048,19 Nombre total de titres avec droits de vote : 43.662.403 (tous des actions ordinaires) Nom...

 PRESS RELEASE

Nyxoah Announces the Signature of a Memorandum of Understanding with S...

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatme...

 PRESS RELEASE

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sh...

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient Mont-Saint-Guibert, Belgique – 18 février 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spéci...

 PRESS RELEASE

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity...

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to suppo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch